1cP-MiPLA

Discovery

MiPLA, the active compound 1cP-MiPLA releases, was first synthesized by David Nichols in 1994 during a study of how structural changes at the amide position affect LSD-like activity.^[1] That research showed MiPLA could fully substitute for LSD in trained animals despite weaker serotonin receptor binding. 1cP-MiPLA itself has no published synthesis record; it most likely emerged from clandestine labs applying the established prodrug technique to the MiPLA scaffold.

The 1-acyl prodrug wave

1cP-MiPLA belongs to a wave of 1-acyl lysergamide prodrugs that appeared on research chemical markets from around 2015 onward. Earlier compounds — 1P-LSD,^[6] 1B-LSD,^[7] 1cP-LSD,^[8] and 1V-LSD^[9] — each convert to LSD in the body. 1cP-MiPLA was the first to apply this prodrug approach to a non-LSD parent compound.

First identification

1cP-MiPLA appeared on online markets around 2020 and was formally identified in 2022 when Japanese researchers detected it in seized blotter products.^[2] That 2023 publication remains the only peer-reviewed scientific report on the compound; its authors noted that 1cP-MiPLA's metabolic pathways and biological activities had not been reported.^[2]

Structural class

1cP-MiPLA belongs to the lysergamide family — compounds built on the ergoline scaffold, the same rigid framework as LSD and related alkaloids. It carries two structural modifications relative to LSD: a cyclopropanoyl group at the indole nitrogen (shared with 1cP-LSD) and a different amide group at the carboxamide end (shared with MiPLA).^[2] That amide change reduces serotonin receptor binding by roughly 2–3× compared to LSD.^[1]

Molecular properties

The molecular formula is C₂₄H₂₉N₃O₂ (molecular weight 391.5 g/mol); no CAS number has been assigned. No published characterization of physical properties exists — the compound has been encountered only as blotter paper and tablet formulations.^[2] The ergoline scaffold contains two chirality centers; only the (6aR,9R) configuration — the same arrangement as LSD — is active at serotonin receptors.^[10]

1cP-MiPLA is presumed to function as a prodrug for MiPLA. Enzymes in the blood and liver cleave the cyclopropanoyl group, releasing MiPLA as the active compound.^[11] This conversion mechanism has been confirmed for five structurally related lysergamides — including 1cP-LSD,^[8] 1P-LSD,^[6] and 1V-LSD^[9] — but has not been confirmed for 1cP-MiPLA specifically.^[2]

Once released, MiPLA activates serotonin receptors in the brain — the established mechanism of classical psychedelic effects. Blocking these receptors in LSD studies eliminates all subjective effects.^[12] Additional activity at other serotonin and dopamine receptors contributes to the full experience.^[13]

Pharmacokinetics

No pharmacokinetic data exist for 1cP-MiPLA or MiPLA. By analogy with LSD, oral absorption peaks around 1.1 hours and active compound clears the body in 2.7–3.5 hours.^[14][15] The prodrug conversion step introduces an additional delay before the active compound reaches circulation, consistent with observations for 1cP-LSD.^[8]

Where it acts

MiPLA — the active compound released from 1cP-MiPLA — activates serotonin receptors on cortical neurons. This increases excitatory brain activity, disrupts the default mode network, and raises connectivity between regions that normally stay separate.^[13][16] The result is reduced filtering of sensory input — the neural basis of psychedelic perceptual expansion.

MiPLA's preserved activity at a secondary serotonin receptor site^[1] may add a calming, introspective dimension alongside the primary perceptual effects.^[17]

Why it matters

One influential model — the REBUS framework — proposes that serotonin receptor activation loosens the brain's reliance on existing assumptions, letting raw sensory input reshape perception more directly. MiPLA's lower receptor affinity would predict a gentler version of this process, consistent with community reports of a shorter and more cognitively manageable experience. LSD-class compounds also promote brain plasticity; whether MiPLA's reduced binding preserves this effect is unknown.

Toxicity

Psychological risks

Acute psychological distress — anxiety, paranoia, thought loops, and panic — can occur at any dose, especially in unsupportive settings or in individuals with existing psychiatric vulnerability.^[12] Ego dissolution at high doses can be severely distressing without preparation.

Rare persistent visual disturbances — after-images, peripheral movement, halos, and visual haze / noise — can follow psychedelic use in some individuals.^[4] LSD-type compounds are most commonly implicated; risk factors include prior psychiatric history and polydrug use.^[4] Psychedelic use can also trigger psychotic episodes in people with a personal or family history of schizophrenia or bipolar disorder.safety citation needed

Tolerance and dependence

Classical serotonergic psychedelics build near-complete tolerance within hours of a single dose.^[19][20] Serotonin receptor density in the brain drops within 24 hours, making a repeat dose much less effective.^[20]

Full cross-tolerance exists with LSD, psilocybin, and mescaline via the shared serotonin receptor mechanism.^[20][16] Classical psychedelics do not activate the brain's reward pathways in the manner of addictive substances — compulsive use is rare.^[16]

Drug interactions

No substance-specific interaction data exist for 1cP-MiPLA. All assessments are extrapolated from LSD-class pharmacology.

Tramadol (dangerous): tramadol blocks serotonin reuptake. Combining it with a serotonergic psychedelic can trigger serotonin syndrome — muscle rigidity, rapid heart rate, high fever, and altered consciousness.^[21] Deaths from tramadol combined with serotonergic agents have been reported.^[5]

MAOIs (dangerous): Monoamine oxidase inhibitors block serotonin breakdown, dramatically amplifying the effects of any serotonin-active compound. The combination has produced fatalities.^[5]

Lithium: Case reports suggest increased seizure risk when lithium is combined with psychedelics.safety citation needed

SSRIs/SNRIs: These antidepressants typically reduce psychedelic effects through receptor competition. Theoretical serotonin syndrome risk exists at high doses, though clinical significance for lysergamides is unclear.safety citation needed

Cannabis (unknown): No published interaction data exist. The combination has not been characterized in controlled studies.

Contraindications

Personal or family history of psychosis or schizophrenia spectrum disorders (absolute): Serotonin receptor activation can trigger or worsen psychotic episodes.safety citation needed

Bipolar disorder (absolute): Risk of triggering manic episodes.safety citation needed

Concurrent tramadol use (absolute): Serotonin syndrome risk.^[21]

Concurrent MAOI use (absolute): Serotonin syndrome risk.^[5]

Heart conditions (relative): Serotonergic psychedelics mildly raise heart rate and blood pressure. These effects may be poorly tolerated by those with pre-existing cardiovascular conditions.safety citation needed

Pregnancy (absolute): No reproductive safety data exist for 1cP-MiPLA, MiPLA, or LSD.safety citation needed

As of 2026, 1cP-MiPLA is not widely scheduled by name in international drug control frameworks. Jurisdictions with broad structural analog laws or blanket novel psychoactive substance legislation may capture it without explicit scheduling.citation needed

Analog and prodrug considerations

The 1-acyl prodrug strategy has been described in forensic literature as a regulatory circumvention mechanism.^[22] 1cP-MiPLA's dual modification increases its structural distance from LSD, potentially complicating prosecution under analog laws. Blanket NPS legislation operates independently of structural similarity and is unaffected by this distance.